Procedure-related radiation and contrast use during TAVI procedures with balloon-expandable versus self-expanding devices
Abstract Background Transcatheter aortic valve implantation (TAVI) procedures show some fundamental differences, depending on the use of balloon-expandable (BEV) or self-expanding (SEV) devices. We aimed to assess, how it translates into contrast use and radiation exposure. Methods From five high volume European centers consecutive patients were included, who underwent transfemoral TAVI procedure. Patient- and procedural characteristics were recorded and compared in relation to the used TAVI device. Results In total 3131 patients were included. 53% were male and the mean age was 80±9 years. 1273 (41%) patients were treated with BEV, while 1858 (59%) with a SEV system. Patients, receiving SEV were older (81±9 vs 79±9 years, respectively; p<0.01) and were more often females (57% vs 33%, respectively; p<0.01). There was also a trend for less peripheral artery disease (14% vs 17%, respectively; p=0.06). Overall total radiation time was 15±9 min., that was markedly shorter for BEV than for SEV (13±8 vs. 17±10 min., respectively; p<0.01). On average 130±65 mL contrast media was used, that was less for BEV than for SEV (104±52 vs. 148±67 mL, respectively; p<0.01) In terms of contrast use, retrievable- and non-retrievable SEVs were comparable (148±71 vs. 146±63 mL, respectively; p=0.41), but both markedly higher, than for BEVs (p<0.01 for both). Non-retrievable SEVs required less radiation (14±7 vs. 18±10 mins, respectively; p<0.01), but still markedly more than BEVs (p<0.01). Conclusion TAVI procedures with BEV require shorter radiation exposure for the team and markedly less contrast, than with SEV. This might be reasonable to consider during patient-tailored procedure planning.Radiation and contrast usage during TAVI
Authors
- Judit Andréka (ORCID: https://orcid.org/0009-0009-8068-090X)
- Michael Adamaszek
- Alexander Wolf (ORCID: https://orcid.org/0000-0003-1541-6351)
- Robertas Pranevičius
- Albrecht Schmidt (ORCID: https://orcid.org/0000-0003-4783-4603)
- Ander Regueiro (ORCID: https://orcid.org/0000-0001-5201-447X)
- S Schnur (ORCID: https://orcid.org/0000-0001-5004-6718)
- C. N. Stark
- Pierre Deharo (ORCID: https://orcid.org/0000-0001-5910-3002)
- Salvatore Brugaletta (ORCID: https://orcid.org/0000-0001-5845-1435)
- Heiko Bugger (ORCID: https://orcid.org/0000-0002-3524-0405)
- Dan Prunea (ORCID: https://orcid.org/0000-0003-3843-6670)
- Gábor G. Tóth (ORCID: https://orcid.org/0000-0002-0283-9091)
- T. Cuisset
Institutions
- Lithuanian University of Health Sciences (LT)
- Medical University of Graz (AT)
- St. Elisabeth-Hospital Bochum (DE)
- Hospital Clínic de Barcelona (ES)
- Hôpital de la Timone (FR)
Publication Details
- Journal
- European Heart Journal
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1093/eurheartj/ehae666.2443
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00